This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Does Aris Mining Corporation (ARMN) Have the Potential to Rally 51.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 51.3% upside potential for Aris Mining Corporation (ARMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ARMNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Aramark (ARMK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Aramark (ARMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARMKNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Helmerich & Payne (HP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Helmerich & Payne (HP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HPPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FOLDNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Conmed (CNMD) Could Surge 25.54%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Conmed (CNMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CNMDNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 130.6% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GHRSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 30.54% Upside in ScanSource (SCSC): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in ScanSource (SCSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SCSCNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Crexendo (CXDO) Have the Potential to Rally 33.63% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Crexendo (CXDO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CXDOPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 50.76% Upside in GRINDR INC (GRND): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for GRINDR INC (GRND) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GRNDNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Abacus Life, Inc. (ABL) Have the Potential to Rally 103.1% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 103.1% in Abacus Life, Inc. (ABL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ABLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Encore Capital Group (ECPG) Could Rally 27.35%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 27.4% upside potential for Encore Capital Group (ECPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ECPGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Slide Insurance Holdings, Inc. (SLDE) Could Surge 33.73%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Slide Insurance Holdings, Inc. (SLDE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SLDENo Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Ultra Clean (UCTT) Could Surge 34.31%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Ultra Clean (UCTT) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
UCTTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VCELNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 26.85% Upside in Controladora Vuela (VLRS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 26.9% upside potential for Controladora Vuela (VLRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
VLRSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Waystar (WAY) Could Rally 38.21%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Waystar (WAY) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WAYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Chime Financial, Inc. (CHYM) Have the Potential to Rally 52.06% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 52.1% upside potential for Chime Financial, Inc. (CHYM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CHYMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KROSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Pharming Group (PHAR) points to a 100.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PHARNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe PRA Group (PRAA) Could Rally 53.69%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for PRA Group (PRAA) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PRAANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 75.15% Upside in Orion Energy Systems (OESX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 75.2% upside potential for Orion Energy Systems (OESX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OESXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 35.5% Upside in SkyWest (SKYW): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.5% in SkyWest (SKYW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SKYWPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 45.88% Upside in OppFi (OPFI): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.9% in OppFi (OPFI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OPFIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%
by Zacks Equity Research
The consensus price target hints at a 62% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANROPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate